Note: Ingredients listed on restricted chemical lists
General Information
Revision date
2004-01-19
Product name
Digoxin Injection USP, 0.25 mg/mL
Product Synonyms
Digoxin Injection USP
supplier name
CURA Pharmaceutical Co., Inc
Manufacturer Name
SAB-Pharma Inc
Emergency telephone
800-424-9300
Icons in SDS
Company Information
company name
CURA Pharmaceutical Co., Inc
GHS Information
Signal word
WARNING!
Section 2
SECTION 2: Hazards identification
Physical State and Liquid. (Clear.) Appearance Emergency Overview WARNING! MAY CAUSE EYE AND SKIN IRRITATION. Avoid contact with eyes, skin and clothing. Avoid exposure during pregnancy. Wash thoroughly after handling.
Principle Routes of Exposure
Intramuscular or intraveinous injection.
Potential Acute Health Effects
Eyes : Hazardous in case of eye contact (irritant). Skin Hazardous in case of skin contact (irritant). Non-sensitizer for skin. Skin inflammation is characterized by itching, scaling, reddening, or, occasionally, blistering. Inhalation This product is a liquid and under normal condition of use is not an inhalation hazard. Ingestion Not available.
Potential chronic health
Carcinogenic Effects Not classified or listed by IARC NTP
Teratogenic Effects
Pregnancy category C. Animal reproduction studies have not been conducted with digoxin. It is also not known whether digoxin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.
Medical Conditions Generally Aggravated by Exposure
Repeated or prolonged exposure is not known to aggravate medical condition. Overexposure: Over-exposure Manifestation of life-threatening toxicity include ventricular tachycardia or ventricular fibrillation, or signs/symptoms progressive bradyarrhythmias, or heart block (more than 10 mg of digoxin in a previously health adult, or more than 4 mg of digoxin in a previously health child, or a steady-state serum concentration greater than 10 ng/mL often results in cardiac arrest). See Toxicological Information (section 11)
